Русский
Sberbank is discussing potentially supplying medical technology solutions to markets in Asia and the Middle East, Sergei Zhdanov, director of the bank’s Health Industry Center, has stated.
Talking at the Innoprom India forum currently being held in New Delhi, he said “We currently have preliminary agreements in the Asian market. We are in the final stages of signing a major contract for 30,000 units in the United Arab Emirates. These are devices, as well as a comprehensive technology solution. Saudi Arabia is also showing keen interest. Although they have already implemented a solution from our competitors, ours offers greater accuracy in certain metrics.”
Zhdanov said that the product is GigaDoc, an AI-powered service from SberMedAI, part of Sberbank’s health division, which assesses an individual’s health status via video analysis of the person’s face. He added that there is also demand for this service in Russia.
Gigadoc is a type of smart mirror, and is based on artificial intelligence, computer vision, and remote photoplethysmography (rPPG). The camera captures small changes in skin color associated with blood flow, and algorithms analyze the received signal. GigaDoc models are trained on a large amount of clinical data. To do a scan, individuals just go to the mirror and look into the camera. GigaDoc will analyze blood pressure, pulse, elasticity of the vascular wall, stress and fatigue levels, body mass index, risk of type II diabetes, as well as cholesterol and glycated hemoglobin levels.
SberMedAI previously reported that it has been developing new AI products since 2026 for entry to the international market. The company had previously noted that it has held talks with potential software clients in India, Madagascar, Kenya, Saudi Arabia, and the UAE. International expansion was one of the measures taken to steer SberMedAI toward profitability, with the company having cut net loss to Russian Accounting Standards 50% to ₽224 million (US$2.65 million) in 2025.
Zhdanov emphasized that the company has already become profitable and that revenue is growing partly on the back of international business. He added “However, this is not solely due to international contracts. Overall, we are still testing the market. I think that we should unveil a really impressive result next year.”
SberMedAI is currently focusing on development and has no plans for an IPO of its assets, Zhdanov said. “It is clear that it is too soon for SberMedAI to launch an IPO. SberMedAI is essentially a Venture Capital backed company that is still finding its market. The AI-in-healthcare business in Russia is challenging, and requires massive investment in R&D. An IPO could be an interesting move in the near future, though the entire focus is currently on the company’s development.”
